$VXRT
Vaxart, Inc. Stock $vxrt

$vxrt Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000143774924034927 Filed on November 13, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$4.933M	$2.101M
YoY Change		134.79%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$4.342M	$4.920M
YoY Change		-11.75%	-29.31%
% of Gross Profit
Research & Development		$15.07M	$15.00M
YoY Change		0.43%	-33.22%
% of Gross Profit
Depreciation & Amortization		$1.000M	$1.000M
YoY Change		0.0%	104.5%
% of Gross Profit
Operating Expenses		$19.41M	$19.92M
YoY Change		-2.58%	-32.29%
Operating Profit		-$14.48M	-$17.82M
YoY Change		-18.78%	-39.43%
Interest Expense		$1.022M	$723.0K
YoY Change		41.36%	57.86%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income		-$14.06M	-$17.36M
YoY Change		-19.0%	-40.73%
Income Tax		$18.00K	$39.00K
% Of Pretax Income
Net Earnings		-$14.08M	-$17.40M
YoY Change		-19.08%	-40.63%
Net Earnings / Revenue		-285.42%	-828.18%
Basic Earnings Per Share		-$0.06	-$0.11
Diluted Earnings Per Share		-$0.06	-$0.11
COMMON SHARES
Basic Shares Outstanding	227.5M	227.4M	152.0M
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$58.71M	$53.00M
YoY Change	10.78%	-53.82%
Cash & Equivalents	$22.04M	$33.20M
Short-Term Investments	$36.68M	$19.80M
Other Short-Term Assets	$439.0K	$3.600M
YoY Change	-87.81%	-35.86%
Inventory
Prepaid Expenses
Receivables	$591.0K	$424.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$66.46M	$57.10M
YoY Change	16.39%	-52.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.476M	$12.93M
YoY Change	-26.69%	5.26%
Goodwill	$4.508M	$4.500M
YoY Change	0.18%	-0.18%
Intangibles	$3.740M	$4.472M
YoY Change	-16.37%	-53.47%
Long-Term Investments
YoY Change
Other Assets	$842.0K	$883.0K
YoY Change	-4.64%	-54.08%
Total Long-Term Assets	$100.2M	$48.54M
YoY Change	106.46%	-11.63%
TOTAL ASSETS
Total Short-Term Assets	$66.46M	$57.10M
Total Long-Term Assets	$100.2M	$48.54M
Total Assets	$166.7M	$105.6M
YoY Change	57.77%	-39.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.524M	$1.339M
YoY Change	88.5%	-83.08%
Accrued Expenses	$6.764M	$5.991M
YoY Change	12.9%	-42.08%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.747M	$1.300M
YoY Change	111.31%	0.0%
Total Short-Term Liabilities	$80.36M	$11.27M
YoY Change	613.21%	-48.17%
LONG-TERM LIABILITIES
Long-Term Debt	$2.128M	$4.600M
YoY Change	-53.74%
Other Long-Term Liabilities	$421.0K	$278.0K
YoY Change	51.44%	28.7%
Total Long-Term Liabilities	$421.0K	$278.0K
YoY Change	51.44%	28.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$80.36M	$11.27M
Total Long-Term Liabilities	$421.0K	$278.0K
Total Liabilities	$98.23M	$34.12M
YoY Change	187.89%	-35.62%
SHAREHOLDERS EQUITY
Retained Earnings	-$464.5M	-$392.2M
YoY Change	18.44%	29.36%
Common Stock	$533.5M	$463.8M
YoY Change	15.04%	8.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$68.44M	$71.52M
YoY Change
Total Liabilities & Shareholders Equity	$166.7M	$105.6M
YoY Change	57.77%	-39.74%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$14.08M	-$17.40M
YoY Change	-19.08%	-40.63%
Depreciation, Depletion And Amortization	$1.000M	$1.000M
YoY Change	0.0%	104.5%
Cash From Operating Activities	-$4.201M	-$15.00M
YoY Change	-71.99%	2.63%
INVESTING ACTIVITIES
Capital Expenditures	$9.000K	$290.0K
YoY Change	-96.9%	-104.1%
Acquisitions
YoY Change
Other Investing Activities	-$17.03M	$5.250M
YoY Change	-424.38%	-121.87%
Cash From Investing Activities	-$17.04M	$4.970M
YoY Change	-442.84%	-115.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-10.00K	-10.00K
YoY Change	0.0%	-100.2%
NET CHANGE
Cash From Operating Activities	-4.201M	-15.00M
Cash From Investing Activities	-17.04M	4.970M
Cash From Financing Activities	-10.00K	-10.00K
Net Change In Cash	-21.25M	-10.04M
YoY Change	111.65%	-75.33%
FREE CASH FLOW
Cash From Operating Activities	-$4.201M	-$15.00M
Capital Expenditures	$9.000K	$290.0K
Free Cash Flow	-$4.210M	-$15.29M
YoY Change	-72.47%	102.54%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Registrant Name EntityRegistrantName	Vaxart, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0000072444
	dei	Entity File Number EntityFileNumber	001-35285
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	59-1212264
	dei	Entity Address Address Line1 EntityAddressAddressLine1	170 Harbor Way, Suite 300
	dei	Local Phone Number LocalPhoneNumber	550-3500
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	228176446
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	227476324
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	153959853
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	153452833
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	700122
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	507020
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q3	us-gaap	Depreciation Depreciation	1000000	usd
	us-gaap	Depreciation Depreciation	2800000	usd
CY2023Q3	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	4500000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	4500000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
	dei	City Area Code CityAreaCode	650
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
	dei	Trading Symbol TradingSymbol	VXRT
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	227479811
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22035000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34755000	usd
CY2024Q3	us-gaap	Short Term Investments ShortTermInvestments	36676000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	4958000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	591000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3008000	usd
CY2024Q3	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	3085000	usd
CY2023Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	0	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4069000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2815000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	66456000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	45536000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9476000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11731000	usd
CY2024Q3	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	60116000	usd
CY2023Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	0	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21536000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24840000	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3740000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4289000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	4508000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	4508000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	842000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	926000	usd
CY2024Q3	us-gaap	Assets Assets	166674000	usd
CY2023Q4	us-gaap	Assets Assets	91830000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2524000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1584000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6764000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5634000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2882000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2703000	usd
CY2024Q3	vxrt	Liability Related To Sale Of Future Royalties Current LiabilityRelatedToSaleOfFutureRoyaltiesCurrent	2747000	usd
CY2023Q4	vxrt	Liability Related To Sale Of Future Royalties Current LiabilityRelatedToSaleOfFutureRoyaltiesCurrent	3803000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	80364000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13724000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15319000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17385000	usd
CY2024Q3	vxrt	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	2128000	usd
CY2023Q4	vxrt	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	2623000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	421000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	293000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	98232000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	34025000	usd
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	23000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	15000	usd
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	533503000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	467731000	usd
CY2024Q3	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	574000	usd
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	366000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-464537000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-409574000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	27000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	68442000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	57805000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	166674000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	91830000	usd
CY2024Q3	us-gaap	Revenues Revenues	4933000	usd
CY2023Q3	us-gaap	Revenues Revenues	2101000	usd
	us-gaap	Revenues Revenues	13515000	usd
	us-gaap	Revenues Revenues	4134000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15066000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15002000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	51559000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	53437000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4342000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4921000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16757000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17144000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	19408000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	19923000	usd
	us-gaap	Operating Expenses OperatingExpenses	68316000	usd
	us-gaap	Operating Expenses OperatingExpenses	70581000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-14475000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-17822000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-54801000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-66447000	usd
CY2024Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1022000	usd
CY2023Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	723000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1941000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2076000	usd
CY2024Q3	vxrt	Noncash Interest Expense On Liability NoncashInterestExpenseOnLiability	631000	usd
CY2023Q3	vxrt	Noncash Interest Expense On Liability NoncashInterestExpenseOnLiability	207000	usd
	vxrt	Noncash Interest Expense On Liability NoncashInterestExpenseOnLiability	2045000	usd
	vxrt	Noncash Interest Expense On Liability NoncashInterestExpenseOnLiability	573000	usd
CY2024Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	22000	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-55000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	26000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-59000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14062000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17361000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-54879000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-65003000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	18000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	39000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	84000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	87000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-14080000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-17400000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-54963000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-65090000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	227452883
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	152026112
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	193655660
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	145810175
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-14080000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-17400000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-54963000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-65090000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	43000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	13000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	28000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	288000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14037000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17387000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-54935000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-64802000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	80014000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2024Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	9000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2475000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	43000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-14080000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	68442000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	57805000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	30000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	312000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9146000	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	208000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	28000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-54963000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	68442000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	85073000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2023Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	8000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3843000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	13000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-17400000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	71521000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	110597000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	17000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	298000	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	39000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10417000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	288000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-65090000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	71521000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-54963000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-65090000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6614000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6293000	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-0	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-55000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	473000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	510000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9146000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	10417000	usd
	vxrt	Noncash Interest Expense On Liability NoncashInterestExpenseOnLiability	2045000	usd
	vxrt	Noncash Interest Expense On Liability NoncashInterestExpenseOnLiability	573000	usd
	vxrt	Noncash Revenue Related To Sale Of Future Royalties NoncashRevenueRelatedToSaleOfFutureRoyalties	3596000	usd
	vxrt	Noncash Revenue Related To Sale Of Future Royalties NoncashRevenueRelatedToSaleOfFutureRoyalties	314000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2417000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	404000	usd
	vxrt	Increase Decrease In Unbilled Receivable IncreaseDecreaseInUnbilledReceivable	3085000	usd
	vxrt	Increase Decrease In Unbilled Receivable IncreaseDecreaseInUnbilledReceivable	-0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1170000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2760000	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	60116000	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-0	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	940000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2699000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-625000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-6092000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37419000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-56932000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	510000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1975000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	120000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	48717000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	27497000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	17500000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	58200000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-31727000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	28848000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	30000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	17000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	208000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	39000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	312000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	298000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	56426000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15309000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12720000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12775000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34755000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46013000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22035000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33238000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22035000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33159000	usd
CY2024Q3	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2023Q3	us-gaap	Restricted Cash RestrictedCash	79000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22035000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33238000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	296000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	87000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	14000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	58700000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"><b>Use of Estimates</b> – The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Actual results and outcomes could differ from these estimates and assumptions.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"><b>Concentration of Credit Risk</b> – Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents, available-for-sale investments and accounts receivable. The Company places its cash, cash equivalents and available-for-sale investments at financial institutions that management believes are of high credit quality. The Company is exposed to credit risk in the event of default by the financial institutions holding the cash and cash equivalents to the extent such amounts are in excess of the federally insured limits. Losses incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any <em style="font: inherit;">one</em> corporate issuer or sector and establishing a minimum allowable credit rating.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
CY2024Q3	us-gaap	Investments And Cash InvestmentsAndCash	58684000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	27000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	-0	usd
CY2024Q3	vxrt	Investments And Cash Fair Value Disclosure InvestmentsAndCashFairValueDisclosure	58711000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22035000	usd
CY2024Q3	us-gaap	Short Term Investments ShortTermInvestments	36676000	usd
CY2023Q4	us-gaap	Investments And Cash InvestmentsAndCash	39714000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000	usd
CY2023Q4	vxrt	Investments And Cash Fair Value Disclosure InvestmentsAndCashFairValueDisclosure	39713000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34755000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	4958000	usd
CY2024Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	590000	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	3000000	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2024Q3	vxrt	Prepaid Clinical And Manufacturing Expenses PrepaidClinicalAndManufacturingExpenses	1637000	usd
CY2023Q4	vxrt	Prepaid Clinical And Manufacturing Expenses PrepaidClinicalAndManufacturingExpenses	984000	usd
CY2024Q3	us-gaap	Prepaid Insurance PrepaidInsurance	488000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	258000	usd
CY2024Q3	us-gaap	Prepaid Rent PrepaidRent	517000	usd
CY2023Q4	us-gaap	Prepaid Rent PrepaidRent	488000	usd
CY2024Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	988000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	752000	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	439000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	333000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4069000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2815000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	19064000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	18562000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9588000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6831000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9476000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11731000	usd
CY2024Q3	us-gaap	Depreciation Depreciation	1000000	usd
	us-gaap	Depreciation Depreciation	2800000	usd
CY2024Q3	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2024Q3	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	60100000	usd
CY2023Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	0	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21500000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24800000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5080000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5080000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1340000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	791000	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3740000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4289000	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	182000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	732000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	731000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	731000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	727000	usd
CY2024Q3	vxrt	Finitelived Intangible Asset Expected Amortization After Year Four FinitelivedIntangibleAssetExpectedAmortizationAfterYearFour	637000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3740000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4511000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4576000	usd
CY2024Q3	vxrt	Accrued Clinical And Manufacturing Expenses Current AccruedClinicalAndManufacturingExpensesCurrent	1309000	usd
CY2023Q4	vxrt	Accrued Clinical And Manufacturing Expenses Current AccruedClinicalAndManufacturingExpensesCurrent	312000	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	371000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	211000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	573000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	535000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6764000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5634000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.098	pure
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y4M24D
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1108000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4511000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5031000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5207000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5389000	usd
CY2024Q3	vxrt	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	1348000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	22594000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4393000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	18201000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2882000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15319000	usd
CY2024Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	1554000	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	1554000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	4661000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	4617000	usd
CY2024Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	10000	usd
CY2023Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	10000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	29000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	41000	usd
CY2024Q3	us-gaap	Variable Lease Cost VariableLeaseCost	496000	usd
CY2023Q3	us-gaap	Variable Lease Cost VariableLeaseCost	459000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	1381000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	1401000	usd
CY2024Q3	us-gaap	Sublease Income SubleaseIncome	20000	usd
CY2023Q3	us-gaap	Sublease Income SubleaseIncome	-0	usd
	us-gaap	Sublease Income SubleaseIncome	54000	usd
	us-gaap	Sublease Income SubleaseIncome	-0	usd
CY2024Q3	us-gaap	Lease Cost LeaseCost	2040000	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	2023000	usd
	us-gaap	Lease Cost LeaseCost	6017000	usd
	us-gaap	Lease Cost LeaseCost	6059000	usd
CY2024Q3	us-gaap	Purchase Obligation PurchaseObligation	8500000	usd
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	vxrt	Common Stock Increase In Shares Authorized CommonStockIncreaseInSharesAuthorized	100000000
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000
	us-gaap	Dividends Dividends	0	usd
CY2024Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	45631718
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	27043664
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	700122
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	507020
CY2024Q2	vxrt	Class Of Warrant Or Right Expirations In Period ClassOfWarrantOrRightExpirationsInPeriod	70663
CY2024Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	140596
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	5685806
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17938726
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.9
	vxrt	Share Based Compensation Arrangement By Share Based Payment Award Shares Available For Grant Decrease From Grants ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantDecreaseFromGrants	7167480
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5248437
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.12
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	38030
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.78
	vxrt	Sharebased Compensation Arrangement By Sharebased Payment Award Nonoption Equity Instruments Released SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsReleased	571884
	vxrt	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Released Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue	1.51
	vxrt	Share Based Compensation Arrangement By Share Based Payment Award Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeited	1872626
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1435332
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.29
	vxrt	Share Based Compensation Arrangement By Share Based Payment Award Canceled ShareBasedCompensationArrangementByShareBasedPaymentAwardCanceled	293568
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	306339
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	3.81
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	18684520
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21407462
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.5
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21407462
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.5
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M29D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	538000	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	12618062
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.02
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y4M24D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	379000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	30000	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	38030
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	7000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	17000	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	54720
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	31000	usd
CY2024Q3	us-gaap	Share Price SharePrice	0.85
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.01
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.78
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2475000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3843000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9146000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10417000	usd
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	15900000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M18D
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-14080000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-17400000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-54963000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-65090000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	227452883
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	152026112
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	193655660
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	145810175
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
CY2024Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25166916
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22346418
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23643677
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20466549

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
vxrt-20240930_cal.xml	Edgar Link	unprocessable
0001437749-24-034927-index-headers.html	Edgar Link	pending
0001437749-24-034927-index.html	Edgar Link	pending
0001437749-24-034927.txt	Edgar Link	pending
0001437749-24-034927-xbrl.zip	Edgar Link	pending
ex_716493.htm	Edgar Link	pending
ex_716494.htm	Edgar Link	pending
ex_716495.htm	Edgar Link	pending
ex_743953.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
slide1.jpg	Edgar Link	pending
vxrt-20240930.xsd	Edgar Link	pending
vxrt20240930_10q.htm	Edgar Link	pending
vxrt-20240930_def.xml	Edgar Link	unprocessable
vxrt-20240930_lab.xml	Edgar Link	unprocessable
vxrt-20240930_pre.xml	Edgar Link	unprocessable
vxrt20240930_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VXRT
Vaxart, Inc. Stock $vxrt

2024 Q4 Form 10-Q Financial Statement

#000143774924034927 Filed on November 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VXRT Vaxart, Inc. Stock $vxrt

2024 Q4 Form 10-Q Financial Statement

#000143774924034927 Filed on November 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VXRT
Vaxart, Inc. Stock $vxrt